Invesco S&P 500 High Div Low Volatility ETF vs TransMedics Group Inc — how do they compare? Invesco S&P 500 High Div Low Volatility ETF trades at $48.82 (market cap $3.14B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Invesco S&P 500 High Div Low Volatility ETF and TransMedics Group Inc are close in size by market cap, and Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 High Div Low Volatility ETF for 125 Days and TransMedics Group Inc for 24 Days on average.
| SPHD | TMDX | |
|---|---|---|
Market Cap | $3.14B | $2.74B |
Volume | 1,461,349 | 949,331 |
52-Week High | $53.55 | $150.42 |
52-Week Low | $46.96 | $61.99 |
Typical Hold Time | 125 Days | 24 Days |
Sector | — | Health |
Enterprise Value | — | $3.13B |
Signals from Pluang's Aura AI — not financial advice
SPHD trades at $48.82, up 1.31% today, but technical indicators show a bearish trend with 17 sell signals versus 4 buy signals. The ETF's moving averages are unanimously bearish while oscillators remain neutral. Recent dividend payments of $0.20 and $0.21 demonstrate its income focus, though financial ratios are unavailable in the current data.
The outlook remains cautious given the bearish technical picture and mixed sentiment. While SPHD offers monthly dividend convenience for income investors, concerns about total return performance versus peers like SCHD present risks. Market volatility and yield sustainability are key considerations for potential investors.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →